Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.
Yan BX, Ma JX, Zhang J, Guo Y, Mueller MD, Remick SC, Yu JJ. Cell Death Dis. 2014;5:e995 PMC4043260.
Non-Programmatically Aligned Cancer Center Members
Thirty years after FDA approval, cisplatin and its homologs continue to play a key role in treating solid tumors. Today, they are used as cancer therapeutic regimens for patients with adenocarcinoma, breast, cervical, colorectal, endometrial, esophageal, gastrointestinal, head & neck, lung, melanoma, non-hodgkins lymphoma, ovarian, pancreatic and testicular cancers. However, platinum-based chemotherapy often results in relatively low survival due to the development of drug resistance. Enhanced repair of platinum-induced DNA-adduct has been suggested as one of the major mechanisms of acquired platinum resistance. Recent research indicates that alteration of the DNA repair system resulting in reduced apoptosis is the leading mechanism of increased DNA repair and platinum-drug resistance. Our goal is to block the DNA repair pathway genes, thereby enhancing cisplatin sensitivity, making cancer chemotherapy more effective.